Long-term efficacy safety analysis of a woven nitinol venous stent for iliac vein obstruction
Vasa · 2025
DOI: 10.1024/0301-1526/a001191 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Vasa, 2025. Verfasst von Michael K W Lichtenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany. Hauptthemen laut MEDLINE: Alloys, Iliac Vein, Stents, Endovascular Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
To assess long-term patency rates, clinical outcomes, and device-related adverse events associated with the use of a dedicated woven nitinol venous stent following venoplasty to treat patients with symptomatic iliac and femoral vein obstruction. Material and methods: This single-center, single-arm, observational study consisted of 25 patients with iliofemoral vein obstructions caused by residual thrombosis, non-thrombotic compression, or post-thrombotic stenosis. Lesions were treated with the blueflow Venous Stent, a closed-cell stent made of woven strands of Nitinol wire. Primary outcome measures were primary patency and sustained clinical success at 3 months while secondary clinical measures included the revised Venous Clinical Severity Score (rVCSS), Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification, and the number of device-related adverse events through 60 months.
Results
Primary patency was 94.7% and sustained clinical success was 76.5% at 3 months. Primary patency was 95.2% and 70% while sustained clinical success was 76.2% and 70% at 12 and 60 months. The mean rVCSS was 7.4 ± 4.0 at baseline, 5.3 ± 1.8 at 3 months, 4.6 ± 1.4 at 12 months, and 2.6 ± 0.9 at 60 months. CEAP classifications at baseline were predominantly C3 (52%) while 36%, 52%, and 40% of scores were C1–C2 at 3, 12, and 60 months. One device-related adverse event (i.e., in-stent restenosis) was reported resulting in reintervention. There were three patient deaths: two from the progression of metastatic cancer and one from a bicycle accident.
Conclusions
This exploratory study demonstrated a primary patency rate of 94.7% and a clinical success rate of 76.2% at 3 months. Patency was 70% with a 65% reduction in the mean rVCSS score from baseline at 5 years (−5.2). The blueflow Venous Stent performed adequately with no safety concerns when used for its intended indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Center, Klinikum Hochsauerland, Arnsberg, Germany.
ORCID-Profile: Michael K W Lichtenberg
Zitieren
APA
Lichtenberg, M. K. W., Stahlhoff, S., Mueller, S., Nazarov, E., Romano, L., & Stavroulakis, K. (2025). Long-term efficacy safety analysis of a woven nitinol venous stent for iliac vein obstruction. Vasa. https://doi.org/10.1024/0301-1526/a001191
Vancouver
Lichtenberg MKW, Stahlhoff S, Mueller S, Nazarov E, Romano L, Stavroulakis K. Long-term efficacy safety analysis of a woven nitinol venous stent for iliac vein obstruction. Vasa. 2025. doi:10.1024/0301-1526/a001191
BibTeX
@article{Lichtenberg2025,
author = {Lichtenberg, Michael K W and Stahlhoff, Stefan and Mueller, Simone and Nazarov, Egor and Romano, Leonardo and Stavroulakis, Konstantinos},
title = {Long-term efficacy safety analysis of a woven nitinol venous stent for iliac vein obstruction},
journal = {Vasa},
year = {2025},
doi = {10.1024/0301-1526/a001191}
}
EUVIMED